XRTX - XORTX Therapeutics Inc.

0.468
0.008   1.731%

Share volume: 27,863
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$0.46
0.01
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-0.15%
1 Month
6.56%
3 Months
-23.40%
6 Months
-42.29%
1 Year
-46.21%
2 Year
-89.48%
Key data
Stock price
$0.47
P/E Ratio 
0.00
DAY RANGE
$0.44 - $0.47
EPS 
N/A
52 WEEK RANGE
$0.37 - $1.41
52 WEEK CHANGE
-$49.14
MARKET CAP 
6.097 M
YIELD 
N/A
SHARES OUTSTANDING 
2.904 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-16-2025
BETA 
-0.13
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$57,032
AVERAGE 30 VOLUME 
$90,429
Company detail
CEO: Allen W. Davidoff
Region: US
Website: xortx.com
Employees: 0
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

Recent news